Where can I find Bristol Myers Squibb's Q1 2025 financial results?

Bristol Myers Squibb's Q1 2025 financial results are detailed in their Earnings Press Release, furnished as Exhibit 99.1 to this 8-K filing, and in the Bristol Myers Presentation, furnished as Exhibit 99.2.

Does the report contain detailed financial numbers?

No, the 8-K filing itself does not contain the detailed financial numbers. It directs investors to the furnished exhibits (Exhibit 99.1 and 99.2) for this information.

What is the significance of the non-GAAP financial information mentioned?

The Earnings Press Release (Exhibit 99.1) includes reconciliations between non-GAAP financial measures and the comparable GAAP financial measures, along with explanations for why these non-GAAP measures are presented. Investors should review these reconciliations for a complete understanding.

Is the information in this 8-K filing considered 'filed' for regulatory purposes?

As stated in the report, the information furnished under Item 7.01 of this 8-K, including Exhibits 99.1 and 99.2, is not deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934, nor is it incorporated by reference into future filings, unless specifically stated.

BMY 8-K: Earnings & Results & Regulation FD

Summary

Bristol Myers Squibb Company (BMY) has filed an 8-K report on April 24, 2025, primarily to announce its first-quarter 2025 financial results and provide related presentations. The filing includes an Earnings Press Release (Exhibit 99.1) and a Bristol Myers Presentation (Exhibit 99.2), both dated April 24, 2025, detailing the company's performance and strategic initiatives for the period. Investors should note that both documents contain references to non-GAAP financial information, with reconciliations provided in the Earnings Press Release. This report serves as the formal vehicle for disseminating BMY's Q1 2025 financial outcomes and outlook. While the 8-K itself does not contain the detailed financial figures, it directs investors to the furnished exhibits for a comprehensive review of operational and financial conditions. The company also highlights that the information provided under Regulation FD is furnished and not deemed 'filed' for certain regulatory purposes, and they reserve the right to remove the presentation from their website.

Key Highlights

1BMY announced its Q1 2025 financial results on April 24, 2025, via an Earnings Press Release (Exhibit 99.1).
2A supplementary Bristol Myers Presentation (Exhibit 99.2) discussing financial and operating initiatives is also available.
3Both the press release and presentation include non-GAAP financial measures.
4Reconciliations for non-GAAP financial measures to GAAP equivalents are provided within the Earnings Press Release.
5The company hosted a conference call and webcast on April 24, 2025, to discuss these results.
6The furnished information is not considered 'filed' under Section 18 of the Exchange Act, limiting certain liabilities.
7BMY reserves the right to remove the presentation materials from its website.

BRISTOL MYERS SQUIBB CO 8-K Report, Financial Results (Apr 24, 2025)

Summary

Key Highlights

Frequently Asked Questions